Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

Posted: April 15, 2023 at 12:26 am

CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced two poster presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 15-18, 2023, in Copenhagen, Denmark.

Excerpt from:
Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

Related Posts